4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2025)
Historic Assets Average for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $448.8 million.
- 4D Molecular Therapeutics' Assets Average fell 2667.38% to $448.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.8 million, marking a year-over-year decrease of 2667.38%. This contributed to the annual value of $450.1 million for FY2024, which is 4961.27% up from last year.
- 4D Molecular Therapeutics' Assets Average amounted to $448.8 million in Q3 2025, which was down 2667.38% from $494.7 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Assets Average ranged from a high of $625.0 million in Q2 2024 and a low of $247.8 million during Q3 2021
- For the 5-year period, 4D Molecular Therapeutics' Assets Average averaged around $386.7 million, with its median value being $339.2 million (2022).
- Per our database at Business Quant, 4D Molecular Therapeutics' Assets Average soared by 10954.75% in 2024 and then plummeted by 2667.38% in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Assets Average (Quarter) stood at $297.1 million in 2021, then decreased by 8.77% to $271.0 million in 2022, then grew by 29.43% to $350.8 million in 2023, then surged by 65.99% to $582.2 million in 2024, then decreased by 22.91% to $448.8 million in 2025.
- Its Assets Average was $448.8 million in Q3 2025, compared to $494.7 million in Q2 2025 and $538.1 million in Q1 2025.